Rino Rappuoli, PhD, is Global Head of Vaccines Research at Novartis Vaccines and Diagnostics and is based in Siena, Italy.
In one of his most recent publications in Nature together with Alan Aderem, they discuss their 2020 vision for vaccines against HIV, tuberculosis and malaria.
Acquired immune deficiency syndrome (AIDS), malaria and tuberculosis collectively cause more than five million deaths per year, but have nonetheless eluded conventional vaccine development; for this reason they represent one of the major global public health challenges as we enter the second decade of the twenty-first century. Recent trials have provided evidence that it is possible to develop vaccines that can prevent infection by human immunodeficiency virus (HIV) and malaria.
Furthermore, advances in vaccinology, including novel adjuvants, prime-boost regimes and strategies for intracellular antigen presentation, have led to progress in developing a vaccine against tuberculosis. Here we discuss these advances and suggest that new tools such as systems biology and structure-based antigen design will lead to a deeper understanding of mechanisms of protection which, in turn, will lead to rational vaccine development.
We also argue that new and innovative approaches to clinical trials will accelerate the availability of these vaccines.
We will have the pleasure to welcome Dr Rappuoli at the 12th annual World Vaccine Congress, where he will be addressing our audience of vaccine executives, manufacturers, scientists, researchers and policy regulators, talking about using reverse vaccinology to identify novel antigens for vaccine development.
He will touch upon the importance of applying genomics, immunology & engineering to rapidly assess vaccine candidates.
All this and much more will be discussed on April 10th 2012. Get your questions ready!
Have a look at the Congress program here.
Ensure you join us at the event at the best possible ticket price by booking your place before the 27th January – register here.